Sign inJoin
Company / Finance

AbCellera Biologics Inc.

ABCL · NASDAQ

Official-source baseline for AbCellera Biologics using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, filed company presentations, and 2026 proxy materials.

FollowAdd to WatchlistAsk Question
NASDAQABCLCoverage BootstrapBiotechnologyAntibody TherapeuticsClinical-Stage Biotech
Latest ReportMay 13, 2026AbCellera Biologics (ABCL) Coverage Bootstrap: cash-rich clinical-stage antibody platform with ABCL635 catalyst riskView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.

Sign in as admin